Correlation Between Transient Elastography and Liver Biopsy in MASLD

Document Type

Conference Proceeding

Publication Date

10-1-2024

Publication Title

Am J Gastroenterol

Abstract

Introduction: The escalating prevalence of metabolic syndrome has led to a parallel rise in NAFLD, thus identifying worsening fibrosis is crucial. Liver biopsy, though the gold standard, is invasive and prone to sampling error. Serologic markers and imaging modalities have limitations in distinguishing MASLD from MASH. Transient Elastography detects hepatic fibrosis effectively. Developing non-invasive methods to distinguish MASLD from MASH is crucial for disease monitoring. Our study aimed to evaluate the concordance of Fibroscan (transient elastography) in predicting degree of fibrosis when compared to Liver Biopsy in patients suspected of having MASLD. Methods: We evaluated patients with metabolic liver disease presenting to a single tertiary center between 2015 and 2020 who underwent confirmatory liver biopsy to assess diagnosis and degree of fibrosis. Baseline characteristics and procedural data were collected. Results: Forty-five patients were included in the study, Baseline characteristics are shown in Table 1. The Spearman correlation coefficient for the association between the estimate of fibrosis on liver biopsy versus the estimate of fibrosis on Fibroscan was 0.249 (P5 0.032), indicating a strong positive monotonic relationship between the 2 variables. The Spearman correlation coefficient for the association between the estimate of fibrosis on liver biopsy versus the estimate of fibrosis on Fib-4. was 0.341 (P = 0.004). The Spearman correlation coefficient for the association between the estimate of fibrosis on liver biopsy versus the estimate of fibrosis on MASLD fibrosis score was 0.400 (P5 0.014). For F0-1, 94% of patients had the same degree of fibrosis on Fibroscan and liver biopsy, 6% had higher degrees of fibrosis on liver biopsy. There were 89% of patients with F2 had the same degree of fibrosis on Fibroscan and liver biopsy, 11% had higher degrees of fibrosis on liver biopsy. Eighty-seven percent of patients with F3 had the same degree of fibrosis on Fibroscan and liver biopsy, 13% had higher degrees of fibrosis on liver biopsy. For F4 100% of patients had the same degree of fibrosis on Fibroscan and liver biopsy. Conclusion: Fibroscan, Fib-4, and MASLD fibrosis score are all valuable methods to accurately estimate fibrosis in patients with MASLD with results comparable to liver biopsy. Fibroscan is a safe, non-invasive, and accurate method for predicting the degree of fibrosis compared to Liver Biopsy in patients suspected of having MASLD.

Volume

119

Issue

10

First Page

S1329

Last Page

S1330

Find It @ Sladen

Share

COinS